等待开盘 06-26 09:30:00 美东时间
-0.700
-3.28%
Kailera Therapeutics (NASDAQ:KLRA) reported quarterly losses of $(3.65) per share which missed the analyst consensus estimate of $(0.68) by 444.78 percent as R&D spend Jumps to $70.9M.
05-27 04:50
William Blair gives Kailera Therapeutics ($KLRA) an Outperform rating. Learn why analysts see a competitive edge in their GLP-1 assets.
05-14 02:43
A company set up to develop Hengrui Pharma's weight-loss drugs has made a stron...
04-24 00:08